Philip H. Howe, PhD, Joins Hollings
RENOWNED CANCER RESEARCHER PHILIP H. HOWE, PHD, JOINS HOLLINGS CANCER CENTER
Howe, Recruited from Cleveland Clinic, is Recognized for Discoveries on the Role of Genes in Tumor Metastasis
July 11, 2011, Charleston, SC – The Hollings Cancer Center at the Medical University of South Carolina (MUSC) is pleased to announce that cancer biologist Philip H. Howe, PhD,
has joined the MUSC faculty as Associate Director of Basic Science for the Hollings Cancer Center. Howe, a professor of biochemistry and molecular biology, holds the Hans and Helen Koebig Chair in Clinical Oncology.
“Dr. Howe brings scientific expertise and leadership in critical areas of research - cancer molecular biology, genetics, and signaling,” said Yusuf A. Hannun, MD, Chairman of MUSC’s Department of Biochemistry and Molecular Biology. “Having him here will lead to exciting collaborations and hopefully important discoveries.”
Howe said he is looking forward to further integrating basic science and clinical research so that discoveries made by scientists can be translated as quickly as possible into clinical trials and ultimately new therapies for patients. Howe, who served on the faculty of the world-renowned Cleveland Clinic for 20 years, said joining a center like Hollings offers experienced scientists the opportunity to apply their expertise in a leaner and more entrepreneurial setting.
“Hollings holds NCI designation, and MUSC is opening new research facilities, both clear signs of an upward trajectory,” Howe said. “I see leaders here who know how to implement a vision, as well as an institutional commitment to providing crucial resources. These are key for progress.”
Earlier this year, Howe published seminal research findings about cellular events, called pathways, which transform normal cells into aggressive tumors. While the study used breast cells, the pathways possess traits that are applicable to other cancers. This new understanding of cancer development could lead to better diagnostic, preventative, and therapeutic procedures for cancer.
Howe holds a number of prestigious grants from the National Cancer Institute (NCI) and has been continually funded for 20 years.